Why the study?
What is the optimal management of malignant pericardial effusion and neoplastic cardiac tamponade?
What is the optimal management of malignant pericardial effusion and neoplastic cardiac tamponade?
This review reappraises the recommended interventions for malignant pericardial effusion and tamponade based on recent therapeutic trials.
Answers are grounded in this paper and cite their sources.
Highlights pericardial predominance in cardiac metastases; leaves open optimal management strategies for malignant effusions.
THE OPTIMAL management of neoplastic cardiac tamponade has been controversial, with ardent proponents of pericardiocentesis (with or without sclerotherapy),¹⁻³surgical decompression,⁴⁻⁸and radiation therapy⁹⁻¹¹as primary therapeutic modalities. In the eight years since this oncologic emergency was last reviewed in this journal,¹²several informative therapeutic trials have been reported that warrant a reappraisal of the recommended interventions for this condition. Epidemiology Although neoplastic involvement of the heart is commonly regarded as a rare condition, a compilation of autopsy series suggests that 3.4% (642/19130) of general autopsies¹³⁻¹⁸and 11.6% (1280/11078) of cancer autopsies¹³⁻²¹demonstrate cardiac metastatic disease. Of 770 cases of cardiac metastases for which adequate information was reported, 533 (69.2%) had involvement of the pericardium.¹³⁻¹⁶,¹⁹,²¹The majority of cases were clinically insignificant; however, 29% of such patients developed symptoms referable to pericardial metastases and 16% developed cardiac tamponade.²²Pericardial lesions were either
No takes yet. Share an insight, caveat, or question.
Oliver W. Press (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: